GlobeNewsWire
14 Jun 2026, 14:21 UTC · 14w ago
Verdict
Headline takes no side. We score CLDX +0.90 across three claims — strongly bullish.
+0.90strongly bullish
More positive than 94% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Phase 2 data for barzolvolimab showed that 64% of patients remained angioedema-free seven months after completing treatment.
More positive than 99% of claims this week
Celldex expects topline data from two Phase 3 CSU trials in Q4 2026, with a planned BLA submission in 2027.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 85% of claims this week
Enrollment is complete for the Phase 3 CSU program, involving 1,939 patients across 43 countries.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 94% of ticker scores this week
The company presented positive long-term Phase 2 data showing sustained off-treatment improvement for barzolvolimab in CSU patients.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
19h ago
−1.2%
Price is moving against the score
$30.88 vs $31.27 close before publication (Jun 12) · not market-adjusted
CLDX chart →
